KIM LLC’s Aspire Biopharma ASBP Stock Holding History

KIM LLC’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-167	Closed	-$2.06M	–	558
2022 Q4	$2.06M	Hold	167	–	–	0.11%	200
2022 Q3	$2.03M	Hold	167	–	–	0.09%	250
2022 Q2	$2M	Buy	+167	New	+$2M	0.1%	259

Other funds holding ASBP

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

KIM LLC's ASBP Position: Q1 2023 in Review

KIM LLC sold out of Aspire Biopharma (ASBP) in Q1 2023, closing a stake of 167 shares — an estimated $2.06M sold.

KIM LLC first reported a position in ASBP in Q2 2022 and held it in 3 quarters. The position peaked at $2.06M in Q4 2022. 57 funds tracked by Wall St. Rank hold ASBP as of Q1 2023.

KIM LLC reported no remaining Aspire Biopharma position as of Q1 2023 after selling out during the quarter.
KIM LLC sold 167 Aspire Biopharma shares in Q1 2023, an estimated $2.06M.
KIM LLC first reported a position in Aspire Biopharma in Q2 2022 and held it in 3 quarters.
KIM LLC's Aspire Biopharma position peaked at $2.06M in Q4 2022.
57 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2023.

Based on KIM LLC's 13F filing for Q1 2023, filed 11 May 2023.